Trial Profile
A Registry of Novel Oral AntiCoagulants and Vitamin K-antagonists In Stroke Patients - a Multi-center Audit Addressing a) Intracerebral Haemorrhage and b) Acute Ischemic Stroke in Patients Treated With Oral Anticoagulants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Cerebral haemorrhage; Stroke
- Focus Therapeutic Use
- Acronyms NOACISP
- 21 Dec 2022 Status changed from recruiting to completed.
- 27 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Oct 2022.
- 27 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2022.